A method for detection and measurement of neutralizing antibody levels to SARS-CoV-2 in a test-specimen, said method comprising: obtaining a whole blood test-specimen from a subject; transferring the test-specimen to a sample well of a test-cassette, wherein the cassette further comprises a blood filter, a conjugate pad, a nitrocellulose membrane and an absorbent pad, wherein the sample pad comprises ACE2 or a functional fragment thereof, wherein the conjugate pad comprises a viral-ACE2-binding protein coupled to a label; adding a buffer; and reading the results from the test-cassette.

The present invention provides a virus collection matrix, including: a porous gel or fibrous structure formed by a positively charged polymer material; and a plurality of ACE 2 receptors. The plurality of ACE 2 receptors are negatively charged, and distributed and covered on the surface of the porous gel or fibrous structure. The whole virus collection matrix is positively charged.

A method of purifying Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EV-CATCHER), designed for high-throughput analysis of low-abundance small-RNA cargos by next-generation sequencing, and use of this method for preparing purified populations of biological particles or cells from a biological sample for in vitro evaluation of a patient's risk of developing and for treating a severe viral infection; for enhancing therapeutic effectiveness of convalescent plasma therapy in a patient at risk for a severe coronavirus infection, and for treating a patient with a severe coronavirus infection, are described.

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.

We describe apparatuses, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of liquid samples in a clinical point of care setting.

Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.

The disclosure provides method, kits, and devices for detecting and/or assessing neutralizing antibodies in a sample, e.g. a biological sample. The detection comprises contacting the sample to an antigen of a virus of interest, and detecting the binding of the one or more IgG3 antibodies to the antigen. The presence of IgG3 antibodies that specifically bind the virus antigen indicates neutralizing antibodies against the virus. The detection protocol can be implemented in a variety of configurations and formats, including ELISA-type and lateral flow formats. The method can be used to assess, e.g., a subject's relative immunity or infection status regarding a particular virus, such as SARS-CoV-2.

This disclosure provides methods of treating a human subject by stimulating chemosensory receptors, such as T2Rs, to increase level of phenotypic expression. Methods may include detecting phenotypic expression deficit by introducing a first agonist capable of first stimulating the chemosensory receptors by first binding thereto; detecting first stimulating; identifying a first deficit in relation to a first reference level, the first deficit being an instance of phenotypic expression deficit. Second stimulating with a second agonist may reduce the phenotypic expression deficit. Third stimulating with a therapeutic agonist may clear a respiratory illness condition by producing innate immune response.